# **Comprehensive Analysis of Opioid Utilization Trends at Semmelweis University: Pharmacological Patterns, Clinical Implications, and Strategic Rotation Frameworks**

## **1\. Introduction: The Geopolitical and Clinical Context of Analgesia**

The alleviation of pain constitutes one of the fundamental pillars of medical practice, recognized universally as a basic human right. Yet, the utilization of opioid analgesics remains a subject of intense complexity, characterized by a stark global dichotomy. While the pharmacological management of pain has advanced significantly over the last century, the distribution and consumption of these essential medicines reveal profound disparities. The World Health Organization (WHO) and the International Narcotics Control Board have repeatedly highlighted that the vast majority of global opioid consumption—approximately 95%—is concentrated in countries representing only 15% of the world's population. This geopolitical imbalance places Hungary, and specifically its leading medical institution, Semmelweis University, in a unique position for analysis. Situated within the Central European context, Hungary has historically exhibited a phenomenon often termed "opiophobia," characterized by stringent regulatory controls and a clinical culture that arguably underutilizes strong opioids compared to Western European and North American counterparts.  
This report provides an exhaustive, expert-level analysis of opioid utilization at Semmelweis University, drawing primarily from internal consumption data recorded during the latter half of 2024 and the first two months of 2025\. The analysis is anchored in the foundational document *“A Semmelweis Egyetem opioid felhasználásának elemzése”* (2025), authored by Dr. Ákos Niedermüller, which offers a granular view of prescribing habits across inpatient and outpatient settings. However, utilization statistics alone are insufficient to drive clinical improvement. To provide a truly comprehensive resource for the university's practitioners, this report synthesizes internal findings with broader pharmacological principles, international conversion guidelines from Scottish and Australian palliative care frameworks , and rigorous safety protocols for special populations, particularly those with renal impairment.  
The objective of this analysis is threefold. First, it seeks to dissect the current prescribing landscape at Semmelweis University, identifying dominant trends such as the prevalence of tramadol in outpatient care and the specific utility of nalbuphine in inpatient wards. Second, it aims to contextualize these findings against the backdrop of Hungarian regulatory history, including the seminal work of János Kabay, whose innovations in morphine extraction in the 1920s revolutionized the field. Third, and perhaps most critically, this report fulfills a strategic objective identified in the source text: the development of a standardized, evidence-based "University Opioid Rotation Protocol." By integrating detailed pharmacodynamic data with practical conversion ratios, this report aims to bridge the gap between theoretical availability and clinical application, ensuring that the management of pain at Semmelweis University aligns with the highest international standards of safety and efficacy.

## **2\. Historical and Pharmacological Foundations of Opioid Use in Hungary**

### **2.1 The Legacy of Alkaloid Chemistry**

To fully appreciate the current landscape of opioid utilization at Semmelweis University, one must acknowledge the historical trajectory of opioid research in Hungary. The source document highlights the pivotal role of János Kabay and the Alkaloida Chemical Factory in the 1920s and 1930s. Kabay’s development of a method to extract morphine directly from dry poppy straw—rather than the labor-intensive incision of green poppy heads—was a revolutionary advancement that democratized access to opiate raw materials. This historical competence in alkaloid chemistry established a foundation for Hungary’s pharmaceutical industry, yet it stands in contrast to the modern clinical reality where opioid utilization rates remain lower than the European average.  
The classification of these agents remains rooted in their receptor affinity and intrinsic activity. The available pharmacopeia at Semmelweis University spans the spectrum from natural opiates, used for millennia, to sophisticated synthetic derivatives developed in the 20th century. Understanding the distinction between these classes is essential for interpreting the utilization data. Natural opiates like morphine serve as the prototype, acting primarily on the mu-opioid receptor (MOR) to produce analgesia, sedation, and euphoria. Semi-synthetic and synthetic derivatives, including oxycodone, fentanyl, and pethidine, have been engineered to modify pharmacokinetic profiles, potency, and side-effect ratios. The document notes that while strong agonists like fentanyl provide linear dose-response curves suitable for titrating against severe cancer pain, weak agonists like tramadol exhibit a "ceiling effect," limiting their utility in escalating pain syndromes.

### **2.2 The "Opiophobia" Phenomenon and Regulatory Landscape**

A recurring theme in the analysis of Hungarian opioid consumption is the concept of underutilization. The *Projektmunka* document cites data from the International Narcotics Control Board (2010), which ranked Hungary 19th out of 42 European countries in per capita opioid use. More recent retrospective studies covering the period from 2006 to 2020 corroborate this, suggesting a persistent trend of underutilization, particularly in the management of oncological pain. This environment is shaped by a rigorous regulatory framework, detailed in the 43/2005 EüM decree and the 66/2012 Government decree, which strictly govern all activities related to narcotic drugs to prevent diversion and misuse.  
While these regulations are essential for public safety, they can inadvertently create administrative barriers that discourage physicians from prescribing strong opioids. The fear of addiction, respiratory depression, and regulatory scrutiny contributes to a clinical culture where weak opioids or adjuvant therapies are often preferred, even when strong opioids might be clinically indicated. This creates a tension between the "right to pain relief" advocated by international bodies and the local realities of prescribing practice. The data from Semmelweis University reflects this tension, showing a heavy reliance on Schedule II (weak) opioids in outpatient settings while reserving Schedule I (strong) opioids for clearly defined, mostly oncological, indications.

## **3\. Analysis of Utilization Trends: Outpatient Care (2024-2025)**

The analysis of outpatient prescription data, sourced from the National Health Insurance Fund (NEAK) and internal electronic systems, reveals a distinct hierarchy in therapeutic preferences. The data covers the entirety of 2024 and the first two months of 2025, providing a clear picture of current practices.

### **3.1 The Dominance of Tramadol: A "Step 2" Stronghold**

The most striking feature of the outpatient data is the overwhelming dominance of tramadol. Identified in the text as the most frequently prescribed weak opioid, tramadol is utilized in a wide array of formulations, including capsules, drops, injections, and extended-release tablets. Furthermore, fixed-dose combinations of tramadol with paracetamol or dexketoprofen are heavily represented.  
This prescribing pattern suggests a profound reliance on "Step 2" of the WHO Analgesic Ladder. Clinicians appear comfortable prescribing tramadol for moderate pain, likely due to its perceived safety profile compared to strong opioids. Tramadol’s dual mechanism of action—acting as a weak mu-opioid receptor agonist and a reuptake inhibitor of serotonin and norepinephrine—provides broad-spectrum analgesia that is effective for both nociceptive and neuropathic pain components. However, the heavy reliance on this agent is not without pharmacological caveats. The document notes that weak agonists like tramadol have a ceiling effect; pushing the dose beyond 400mg/day yields little additional analgesia but significantly increases the risk of seizures and serotonergic toxicity.  
The prevalence of tramadol/dexketoprofen combinations is particularly interesting given that the text notes these are not subsidized by the national insurance scheme (NEAK), implying that patients or the institution bear the full cost. This suggests a clinical perception of efficacy that outweighs economic disincentives. The high volume of tramadol prescriptions may also reflect the "weak opioid trap," where clinicians delay the transition to strong opioids (Step 3\) due to administrative burdens or safety concerns, potentially leaving patients with severe pain inadequately treated once the ceiling of tramadol efficacy is reached.

### **3.2 Fentanyl Transdermal Systems: The Backbone of Chronic Care**

Among strong opioids, transdermal fentanyl patches represent the cornerstone of outpatient management for severe chronic pain. The national data cites over 221,000 boxes dispensed in 2024, with Semmelweis University contributing a monthly average of approximately 48 to 55 prescriptions in the analyzed period. The preference for the transdermal route is clinically logical for the management of stable, chronic cancer pain. Patches provide continuous drug delivery, maintaining stable serum concentrations and avoiding the peaks and troughs associated with short-acting oral formulations. This improves sleep quality and compliance, critical factors in palliative care.  
However, the document raises significant safety concerns regarding fentanyl. It explicitly mentions the risks of "overuse" and "misuse," alongside the euphorigenic potential that can lead to dependence. Fentanyl’s narrow therapeutic index means that inappropriate dosing or application of heat (which accelerates absorption) can lead to fatal respiratory depression. Despite these risks, the prescription volume indicates that for the oncology population—which constitutes over 51% of the indications (BNO Code C)—fentanyl remains the preferred strong opioid. The slight increase in fentanyl prescription volume observed in January and February 2025 suggests that, unlike the declining national trend seen in previous years, the demand for high-potency analgesia within the university’s patient catchment area remains robust.

### **3.3 Indication Analysis: Oncology vs. Musculoskeletal Pain**

The breakdown of prescriptions by International Classification of Diseases (BNO) codes offers insight into the patient populations driving opioid demand.

* **Oncology (Code C):** Accounting for over 51% of all opioid prescriptions, cancer pain is the primary driver of utilization. This aligns with global standards where opioids are the mainstay of cancer pain management (Category I.A recommendation).  
* **Musculoskeletal (Code M):** Representing 15-16% of prescriptions, this category reflects the burden of chronic non-cancer pain (CNCP). The use of opioids for CNCP is controversial globally due to the lack of long-term efficacy data and the risk of dependence. The significant but minority share of M-code prescriptions at Semmelweis suggests a cautious approach to CNCP, avoiding the "epidemic" levels of prescribing seen in the United States, where widespread opioid use for non-cancer pain fueled a public health crisis.  
* **Symptoms (Code R):** The 10% of prescriptions for "symptoms and signs not elsewhere classified" likely represents palliative management of dyspnea or pain in patients without a definitive cancer diagnosis or in the terminal phase of other chronic diseases.

## **4\. Analysis of Utilization Trends: Inpatient Care**

The inpatient setting presents a markedly different pharmacological profile, necessitated by the acute nature of the patient population, the availability of intravenous access, and the requirement for rapid titration. The data from the university pharmacy reveals distinct preferences for parenteral formulations.

### **4.1 The Role of Nalbuphine: A Divergence from Standard Practice**

One of the most notable findings in the inpatient data is the substantial consumption of Nalbuphine injection, with approximately 115 boxes consumed per month in late 2024\. Nalbuphine is a mixed agonist-antagonist opioid (kappa-agonist/mu-antagonist). Its pharmacological profile is distinct: it produces analgesia primarily through kappa receptor activation while antagonizing the mu receptor.  
The document justifies this high usage by citing Nalbuphine’s favorable safety profile compared to morphine. Specifically, Nalbuphine exhibits a "ceiling effect" for respiratory depression; beyond a dose of roughly 30mg, further increases do not proportionally depress respiration. This safety margin makes it an attractive option for general wards or postoperative settings where intensive respiratory monitoring may not be feasible. Furthermore, literature suggests it has a lower incidence of pruritus and nausea compared to morphine.  
However, the widespread use of Nalbuphine introduces complexity in opioid rotation. Because it is a mu-receptor antagonist, administering Nalbuphine to a patient who is physically dependent on a pure mu-agonist (such as a patient on a home Fentanyl patch) can precipitate acute opioid withdrawal. This necessitates rigorous medication reconciliation protocols at admission to ensure that chronic pain patients are not inadvertently thrown into withdrawal by a well-intentioned dose of Nalbuphine.

### **4.2 Anesthetic Considerations: Sufentanil and Fentanyl**

The inpatient data also highlights the heavy use of short-acting, high-potency opioids in the perioperative setting.

* **Fentanyl Injection:** With consumption reaching up to 527 boxes/month in early 2025, fentanyl remains the workhorse of intraoperative analgesia.  
* **Sufentanil:** The consumption of Sufentanil (140-155 boxes/month) is significant. The document notes that Sufentanil has a higher affinity for the mu-opioid receptor than fentanyl, allowing for smaller doses and, crucially, better maintenance of hemodynamic stability. This makes it the agent of choice for cardiovascular surgeries or hemodynamically compromised patients, justifying its higher acquisition cost. The distinct pharmacokinetic profile of sufentanil, with its rapid equilibration and shorter context-sensitive half-life, offers precise control during anesthesia.

### **4.3 The Persistence of Pethidine**

Despite global trends moving away from its use, Pethidine remains in the university’s inventory, with consumption averaging around 28 boxes per month. Pethidine (Meperidine) acts as a mu-agonist but is metabolized to norpethidine, a neurotoxic metabolite that can accumulate and cause tremors, myoclonus, and seizures. This risk is exacerbated in patients with renal impairment or those taking other serotonergic medications. Most modern guidelines, including those for renal failure, explicitly contraindicate Pethidine for chronic use. Its continued presence at Semmelweis likely reflects specific niche indications (such as the treatment of post-anesthetic shivering) or entrenched historical prescribing habits. A review of Pethidine usage could be a target for future opioid stewardship initiatives.

## **5\. Strategic Gap Analysis: The Lack of Transmucosal Fentanyl**

A critical finding in the source document is the identification of a significant gap in the available pharmacopeia: the absence of rapid-onset transmucosal fentanyl formulations (e.g., buccal tablets, sublingual sprays, lozenges) in Hungary.

* **Clinical Impact:** Rapid-onset fentanyl is the gold standard for managing "breakthrough pain" in cancer patients—transient flares of severe pain that occur despite stable background analgesia. These episodes typically peak within minutes and last for 30-60 minutes.  
* **The Mismatch:** Oral morphine, the standard alternative, takes 30-45 minutes to reach peak effect. By the time the morphine takes effect, the breakthrough episode may have already resolved, leaving the patient sedated without having relieved the pain at its peak.  
* **Current Workarounds:** The document implies that clinicians must rely on slower-acting oral opioids or invasive parenteral injections to manage these crises. The lack of transmucosal options represents a significant barrier to optimal palliative care and is highlighted as a deficiency compared to the range of agents available internationally.

## **6\. Developing the University Opioid Rotation Protocol**

The *Projektmunka* document explicitly sets the creation of a "University Opioid Rotation Table" as a primary objective to support the rationalization of opioid use. Opioid rotation (switching from one opioid to another) is a complex clinical maneuver used to improve analgesia or reduce side effects (opioid-induced neurotoxicity). Because cross-tolerance is incomplete, simply calculating the equianalgesic dose is dangerous; a dose reduction is mandatory.  
Based on the synthesis of international guidelines from the Scottish Palliative Care Guidelines , Eastern Palliative Care (Australia) , and the eviQ Cancer Treatments Online , the following comprehensive rotation framework is proposed for implementation at Semmelweis University.

### **6.1 The Mathematical Model: Oral Morphine Equivalents (OME)**

The foundation of any rotation is the conversion of all opioid doses into a single common currency: the Oral Morphine Equivalent (OME) or Oral Morphine Equivalent Daily Dose (oMEDD).

* **Step 1:** Calculate the Total Daily Dose (TDD) of the current opioid (including regular and breakthrough doses used).  
* **Step 2:** Convert the TDD to the 24-hour Oral Morphine Equivalent using standard ratios.  
* **Step 3:** Convert the OME to the *new* opioid dose using the reverse ratio.  
* **Step 4 (CRITICAL):** Apply a **Dose Reduction**. A reduction of **25-50%** is standard to account for incomplete cross-tolerance and inter-patient variability.  
  * *25% reduction:* For stable patients switching for convenience.  
  * *50% reduction:* For elderly, frail patients, or those with renal/hepatic impairment.  
* **Step 5:** Calculate the new breakthrough dose (1/6th of the new Total Daily Dose).

### **6.2 Proposed Conversion Table for Semmelweis University**

This table aggregates data from multiple reliable sources to provide ranges suitable for the Hungarian pharmacopeia.

| Drug | Formulation | Conversion Factor TO Oral Morphine | Conversion Factor FROM Oral Morphine | Notes |
| :---- | :---- | :---- | :---- | :---- |
| **Morphine** | Oral | 1 | 1 | Reference Standard |
| **Morphine** | SC / IV | Multiply SC dose by 2 \- 3 | Divide Oral dose by 2 \- 3 | Parenteral is 2-3x more potent |
| **Oxycodone** | Oral | Multiply Oxy dose by 1.5 | Divide Oral Morphine by 1.5 | Oxycodone is \~1.5x more potent |
| **Oxycodone** | SC / IV | Multiply SC dose by 3 \- 4 | Divide Oral Morphine by 3 \- 4 | SC Oxycodone is highly potent |
| **Tramadol** | Oral / Inj | Divide Tramadol by 10 | Multiply Oral Morphine by 10 | Weak opioid. 100mg Tramadol ≈ 10mg Morphine |
| **Dihydrocodeine** | Oral | Divide DHC by 10 | Multiply Oral Morphine by 10 | Weak opioid. 240mg DHC ≈ 24mg Morphine |
| **Hydromorphone** | Oral | Multiply HM dose by 5 | Divide Oral Morphine by 5 | 5x more potent than Morphine |
| **Fentanyl** | SC / IV | Multiply Fentanyl (mcg) by 0.15 | Divide Oral Morphine (mg) by 0.15 | *Complex.* 100mcg SC Fentanyl ≈ 10-15mg Oral Morphine |

### **6.3 Transdermal Fentanyl Rotation Guide**

Given the high usage of patches at the university , a specific transdermal guide is essential. Fentanyl patches are unique because the dose is expressed in micrograms per *hour*, while morphine is milligrams per *day*.

| Fentanyl Patch Strength (mcg/hr) | Approx. Oral Morphine Equivalent (mg/24h) | Suggested Breakthrough Dose (Oral Morphine) |
| :---- | :---- | :---- |
| **12** | 30 \- 45 mg | 5 \- 10 mg |
| **25** | 60 \- 90 mg | 10 \- 15 mg |
| **50** | 120 \- 150 mg | 20 \- 30 mg |
| **75** | 180 \- 225 mg | 30 \- 40 mg |
| **100** | 240 \- 300 mg | 40 \- 60 mg |
| \*\* |  |  |

*Clinical Alert:* Fentanyl patches take 12-24 hours to reach effective serum levels. When rotating *to* a patch, the patient’s previous opioid must be continued (at 100% or tapering dose) for the first 12 hours. Conversely, when rotating *off* a patch, a subcutaneous depot of drug remains, so the new opioid should be started cautiously (e.g., at 50% dose) or delayed.

### **6.4 The Methadone Rotation Algorithm**

Methadone is available at Semmelweis (5mg tablets) but is notably difficult to use due to its variable half-life (15-60 hours) and accumulation risk. Standard linear conversion tables are dangerous for methadone. The "Ripamonti" or "Mercadante" ratios are generally used, which change based on the prior morphine dose :

* **Low Dose Morphine (\<100mg/day):** Conversion Ratio \~ 3:1 to 4:1 (Morphine:Methadone).  
* **Medium Dose Morphine (100-300mg/day):** Ratio \~ 8:1 to 10:1.  
* **High Dose Morphine (\>300mg/day):** Ratio can exceed 12:1 or even 20:1.

*Recommendation:* Methadone rotation should be reserved for specialists or inpatient settings where QTc intervals and respiratory status can be monitored during the 5-7 day equilibration period.

## **7\. Clinical Safety Protocols for Special Populations**

The university’s large internal medicine and oncology caseload implies a high prevalence of patients with renal and hepatic dysfunction. The provided research snippets highlight that standard dosing in these groups can lead to the accumulation of toxic metabolites.

### **7.1 Renal Impairment Protocols (GFR \< 30 ml/min)**

The kidney is the primary route of excretion for morphine metabolites. In severe renal failure (GFR \< 30), the accumulation of Morphine-3-glucuronide (M3G) can cause neuroexcitation (myoclonus, seizures), while Morphine-6-glucuronide (M6G) accumulation causes profound sedation and respiratory depression.  
**Proposed Renal Safety Algorithm for Semmelweis:**

1. **Contraindicated / Avoid:**  
   * **Pethidine:** Metabolite norpethidine causes seizures. Strictly contraindicated.  
   * **Codeine / Dihydrocodeine:** Metabolites accumulate unpredictably; high toxicity risk.  
   * **Morphine:** Generally avoid. If necessary, reduce dose by 50-75% and extend interval, or switch to a safer agent.  
2. **Use with Caution:**  
   * **Oxycodone:** Metabolites accumulate but are less neurotoxic than morphine. Requires dose reduction (50%) and careful monitoring.  
   * **Hydromorphone:** Accumulates less than morphine but still requires caution.  
3. **Preferred Agents:**  
   * **Fentanyl / Sufentanil:** Metabolized by the liver to inactive metabolites. These are the safest strong opioids for renal failure. However, patches may have variable absorption in uremic patients with low muscle mass.  
   * **Methadone:** Metabolized by the liver and excreted in feces. Safe for renal failure but difficult to titrate.  
   * **Alfentanil:** Useful for short-term inpatient use; not removed by dialysis.

\#\#\# 7.2 Hepatic Impairment Considerations While less emphasized in the text, hepatic impairment affects the metabolism of most opioids.

* **Methadone:** Bioavailability can increase drastically in liver failure; avoid in severe impairment.  
* **Oxycodone/Naloxone (Targin):** This combination is contraindicated in moderate-to-severe hepatic impairment. The liver normally metabolizes the naloxone (first-pass effect); if the liver fails, naloxone enters systemic circulation and antagonizes the analgesic effect of the oxycodone, precipitating pain or withdrawal.

## **8\. Strategic Recommendations and Future Directions**

The analysis of the 2024-2025 data, combined with the review of international best practices, points to several actionable recommendations for Semmelweis University.

1. **Opioid Stewardship Program:** Establish a formal oversight committee to review Pethidine usage. Given its toxicity profile and the availability of safer alternatives, its use should be restricted to specific indications (e.g., post-anesthetic shivering) and phased out for analgesia.  
2. **Nalbuphine Safety Protocol:** Develop a mandatory check in the electronic prescribing system to prevent the administration of Nalbuphine to patients already prescribed pure agonist opioids (e.g., fentanyl patches), thereby preventing iatrogenic withdrawal.  
3. **Education on "Weak Opioid" Limitations:** Conduct educational seminars on the "ceiling effect" of tramadol. Encourage earlier rotation to low-dose strong opioids (e.g., 5-10mg Morphine or Oxycodone) rather than maximizing tramadol/NSAID combinations, which increases organ toxicity risk without analgesic benefit.  
4. **Advocacy for Transmucosal Fentanyl:** The university, as a leading medical center, should advocate at the national level (NNGYK/NEAK) for the registration and reimbursement of transmucosal fentanyl products to manage breakthrough cancer pain effectively.  
5. **Digital Integration of Rotation Tables:** The tables proposed in Section 6 should be integrated into the university’s Hospital Information System (HIS). An automated calculator that inputs the current dose and outputs the recommended conversion (with built-in safety reductions) would significantly reduce prescribing errors.

## **9\. Conclusion**

The analysis of opioid utilization at Semmelweis University depicts an institution that is effectively managing a high volume of complex oncological and surgical pain despite the systemic constraints of the Hungarian pharmaceutical landscape. The data reveals a heavy reliance on **Tramadol** for moderate pain and **Transdermal Fentanyl** for severe chronic pain, patterns that align with the specific regulatory and economic incentives of the region.  
However, the analysis also uncovers critical areas for clinical optimization. The widespread use of **Nalbuphine** requires careful stewardship to avoid precipitation of withdrawal in tolerant patients. The persistent use of **Pethidine**, albeit low, warrants review given its toxicity profile in renal failure. Most importantly, the lack of rapid-onset transmucosal fentanyl represents a significant barrier to the optimal management of breakthrough pain, forcing clinicians to rely on less ideal alternatives.  
The **Opioid Rotation Protocol** and conversion frameworks provided in this report directly address the objective set out in Dr. Niedermüller’s project. By implementing these standardized conversion tools, adopting rigorous renal safety guidelines, and moving towards "Opioid Stewardship," Semmelweis University can enhance patient safety, rationalize opioid consumption, and ensure that the "fundamental human right" to pain relief is delivered with both compassion and pharmacological precision.  
**Table 1: Summary of Key Opioid Characteristics Relevant to Semmelweis University**

| Opioid | Class | Potency (vs Morphine) | Key Advantage | Key Risk / Limitation |
| :---- | :---- | :---- | :---- | :---- |
| **Morphine** | Strong Agonist | 1x | Gold standard; versatile | Active metabolites accumulate in renal failure. |
| **Oxycodone** | Strong Agonist | 1.5-2x | High oral bioavailability | Metabolites accumulate in renal failure. |
| **Fentanyl** | Strong Agonist | 100x | Safe in renal failure; stable patch delivery | Patch not for unstable pain; heat increases absorption. |
| **Tramadol** | Weak Agonist | 0.1x | Lower resp. depression risk; dual mechanism | Ceiling effect; seizure risk; serotonin syndrome. |
| **Nalbuphine** | Agonist-Antagonist | 1x | Ceiling on resp. depression; safe for mild pain | Precipitates withdrawal in opioid-dependent patients. |
| **Sufentanil** | Strong Agonist | 1000x | Hemodynamic stability; high potency | High cost; primarily anesthetic use. |
| **Pethidine** | Strong Agonist | 0.1x | Treating rigors | Neurotoxic metabolite (norpethidine); seizures. |
| **Methadone** | Strong Agonist | Variable | NMDA antagonism; good for neuropathic pain | Complex kinetics; QT prolongation; accumulation. |

### **In-Text Citations Overview**

* : *A Semmelweis Egyetem opioid felhasználásának elemzése* (Project Document).  
* : International Guidelines (Scottish Palliative Care, Eastern Palliative Care, eviQ).  
* : Specific scientific studies and clinical fact sheets regarding pharmacology, safety, and renal dosing.

#### **Works cited**

1\. Trends in opioid utilization in Hungary, 2006–2020: A nationwide retrospective study with multiple metrics, https://real.mtak.hu/150760/1/EuropeanJournalofPain-2022-Engi-TrendsinopioidutilizationinHungary20062020Anationwideretrospective.pdf 2\. Opioid Conversions \- Eastern Palliative Care, https://www.epcvic.org.au/uploads/778/64/Opioid-Conversion-Workbook-August-2024.pdf 3\. Opioid/opiate conversion tables – switching between opioid ..., https://www.rightdecisions.scot.nhs.uk/scottish-palliative-care-guidelines/medicines-information/choosing-and-changing-opioids-opiates-convertingswitching/opioidopiate-conversion-tables-switching-between-opioid-medicines/ 4\. A Comparision of Nalbuphine with Morphine for Analgesic Effects and Safety : Meta-Analysis of Randomized Controlled Trials \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC4454168/ 5\. Nalbuphine: Package Insert / Prescribing Information / MOA \- Drugs.com, https://www.drugs.com/pro/nalbuphine.html 6\. Nalbuphine | Palliative Care Network of Wisconsin, https://www.mypcnow.org/fast-fact/nalbuphine/ 7\. Sufentanil: Pharmacolgy and Current Applications in Clinical Practice \- JSciMed Central, https://www.jscimedcentral.com/jounal-article-info/Journal-of-Pharmacology-and-Clinical-Toxicology/Sufentanil:-Pharmacolgy-and-Current-Applications-in-Clinical-Practice-10739 8\. Opioid Use in Renal Failure \- Palliative Care Network of Wisconsin, https://www.mypcnow.org/fast-fact/opioid-use-in-renal-failure/?print=print 9\. OPIOID DOSING AND CONVERSION CALCULATIONS \- Hospice and Palliative Nurses Association, https://www.advancingexpertcare.org/wp-content/uploads/2023/08/NRG\_Opiod-Dosing-3.pdf 10\. 3201-Opioid Conversion Calculator | eviQ, https://www.eviq.org.au/clinical-resources/eviq-calculators/3201-opioid-conversion-calculator 11\. A review of common methods to convert morphine to methadone \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3715153/ 12\. Advanced Opioid Conversion Calculator \-Morphine Equivalents \- GlobalRPH, https://globalrph.com/medcalcs/advanced-opioid-conversions-equianalgesic-morphine-equivalents/ 13\. Renal disease in the last days of life \- Right Decisions, https://rightdecisions.scot.nhs.uk/scottish-palliative-care-guidelines/last-days-of-life/renal-disease-in-the-last-days-of-life/?searchTerm=fentanyl 14\. Use of opioids in Patients with Impaired Renal Function \- Palliative Drugs, https://www.palliativedrugs.org/download/08\_06\_Prescribing%20Opioids%20in%20Renal%20Patients%5B1%5D%5B1%5D.pdf